Welcome to our dedicated page for Paysign SEC filings (Ticker: PAYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Paysign, Inc. (PAYS) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. As an SEC registrant under file number 001-38623, Paysign submits current reports on Form 8-K and other required filings that document financial results, material events and corporate governance matters related to its fintech and healthcare-focused operations.
Recent Form 8-K filings include items under Results of Operations and Financial Condition, where Paysign furnishes press releases detailing quarterly financial results. These exhibits describe total revenues, the breakdown between plasma revenue, pharma patient affordability revenue and other revenue, as well as information on gross profit, operating expenses, EBITDA, Adjusted EBITDA and related non-GAAP metrics. Such filings help readers understand how the company’s prepaid card programs, patient affordability offerings, donor compensation solutions and payment processing activities contribute to its financial performance.
Other 8-K filings address Regulation FD Disclosure items, including information about stockholder derivative actions and proposed settlements. These documents outline the nature of the litigation, the terms of stipulations and agreements of settlement, and the anticipated corporate governance reforms and procedures that the company has agreed to adopt, subject to court approval. Exhibits may include notices of pendency and proposed settlement and related press releases.
Through Stock Titan, users can monitor Paysign’s real-time updates from EDGAR and review filings that reference key exhibits, such as earnings press releases and settlement documentation. The filings page is a resource for examining how Paysign reports on its plasma and pharma patient affordability businesses, restricted cash for customer card funding and pharmaceutical claim reimbursements, and other material developments affecting its fintech healthcare ecosystem.
AI-powered tools on the platform can assist in summarizing lengthy filings, highlighting important sections related to revenue composition, cost structure, litigation, governance changes and other disclosures, helping users interpret complex regulatory documents more efficiently.
Key results (Q2 2025): Total revenues $19,078,353; gross profit $11,755,165; net income $1,387,761; gross margin 61.6%.
Six months YTD: Revenues $37,676,502; net income $3,973,861; gross margin 62.2%. Total assets $193,896,201; total liabilities $151,688,242; cash and restricted cash $113,913,123.
Drivers and transactions: Revenue growth driven by pharma industry (+$5,079,005; +189.9% Q2; +$11,309,014; +223.3% YTD). Plasma revenue declined (-4.7% Q2; -6.9% YTD). On March 19, 2025 Paysign acquired Gamma Innovation LLC: preliminary purchase consideration $15,558,637; identifiable intangible assets $11,071,000; goodwill $4,487,637; earn-out contingent consideration revised to $990,000.
Paysign, Inc. (PAYS) – Form 4 insider activity
Chief Legal Officer Robert Strobo reported two transactions. On 31 Jul 2025 he vested/exercised 64,000 restricted shares (Code “M”) at $0, lifting his direct holding to 273,811 shares. On 4 Aug 2025 he sold 26,521 common shares in the open market (Code “S”) at a weighted-average price of $7.0851 (range $6.9976–$7.1530). Post-sale he directly owns 247,290 shares.
The stock grant vests 20 % annually from 31 Jul 2022 through 31 Jul 2027. Derivative table shows 128,000 shares still underlying outstanding awards.
- Net change: +37,479 shares retained.
- Portion sold: ≈41 % of newly vested shares.
No earnings, guidance, or other financial disclosures are included.
Paysign, Inc. (PAYS) Form 4 highlights insider activity by CFO Jeffery B. Baker.
- On 07/31/2025 Baker received 64,000 common shares as part of a previously granted restricted stock award; the grant vests 20 % annually from 07/31/2022 through 07/31/2027 and carried a $0 exercise price.
- On 08/04/2025 he sold 30,396 shares at a weighted-average price of $7.0851 (sales occurred within a price range of $6.9976–$7.1530).
Following these transactions Baker directly owns 252,273 common shares and retains derivative rights to 128,000 additional shares tied to the same award. The filing discloses no new option grants, compensation changes or company-specific events and indicates the sale was executed under a Rule 10b5-1 plan. Overall, the activity appears routine, with the executive maintaining a substantial equity stake.
Paysign, Inc. (PAYS) Form 4: Chief Payments Officer & Director Matthew Lanford reported two transactions. On 31-Jul-2025 he vested and acquired 64,000 common shares at a $0.00 exercise price from a 2022 restricted-stock grant (one-fifth vests annually through 31-Jul-2027). On 04-Aug-2025 he sold 26,367 shares on the open market at a weighted-average $7.0851 (range $6.9976-$7.1530). After these trades he directly owns 147,364 common shares and holds 128,000 unvested/derivative shares under the same grant. The filing was submitted as a single-person report and is not 10b5-1 designated.